Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a publicly held, clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.

Acurx Pharmaceuticals Inc

Phase 2 Trial Data Show That Novel Antibiotic Led to 96% Cure Rate for C diff Infection

In a recent phase 2 trial, approximately 96% of patients with Clostridioides difficile (C diff) infection (CDI) who received antibiotic iberzaplstat (Acrux Pharmaceuticals) experienced clinical cure, according to a press release. Iberzaplstat demonstrated non-inferiority to vancomycin (Vancocin; Pfizer)—a standard of care antibiotic used to treat CDI—which had a cure rate of approximately 81%, according to a previous assessment.

https://lnkd.in/gBtRZzz2

#nasdaq #acxp #antibiotics #acurx
Acurx Pharmaceuticals Inc David Luci

World AMR Awareness Week Reflections at Acurx Pharmaceuticals Inc 
 
On the heels of World AMR Awareness Week 2023, Acurx Pharmaceuticals reflects on a week of enlightenment and shared insights. In the fight against Antimicrobial Resistance (AMR), our global community united to address the crisis, acknowledging both progress and challenges.
 
This year's World AMR Awareness Week showcased a resilient commitment from scientists, doctors, researchers, and policymakers worldwide. Positive strides include the World Health Organization's new AMR research agenda, outlining crucial priorities. However, the battle against AMR remains intense, with national outbreaks of resistant infectious bacteria and fungi amplifying the urgency for innovative solutions.
 
Despite the obstacles, hope shines through legislative initiatives like the PASTEUR Act, offering a potential game-changer in the broken marketplace for AMR therapies. Acurx Pharmaceuticals stands steadfast, aligning our mission with the global pursuit of solutions.
 
As we move forward, the imperative to act against AMR is clearer than ever. Acurx Pharmaceuticals remains dedicated to developing antibiotics that align with the highest standards of public health, standing at the forefront of the fight against drug-resistant superbugs.
 
#AMRAwareness #GlobalHealth #Innovation #AcurxPharma

Acurx Pharmaceuticals Inc: Pioneering Antibiotic Innovation during National Entrepreneurship Month! Join us in celebrating National Entrepreneurship Month as we drive innovation, tackle healthcare challenges, and contribute to global health!
 
#AcurxPharmaceuticals #AntibioticInnovation #EntrepreneurshipMonth #GlobalHealthHeroes

Wishing you a Healthy and Happy Thanksgiving! 

At Acurx Pharmaceuticals Inc, we're grateful for the opportunity to make a difference in healthcare. As we gather with loved ones to give thanks, we also reflect on the importance of health and well-being.

May your Thanksgiving be filled with joy, gratitude, and delicious moments shared with family and friends. 

#Thanksgiving #Health #Gratitude #AcurxPharma #HealthyHolidays #ACXP

Acurx Pharmaceuticals Inc is proud to celebrate U.S. Antibiotic Awareness Week (USAAW) from November 18-24, bringing attention to the vital importance of responsible antibiotic and antifungal use. Our participation in U.S. Antibiotic Awareness Week aligns with our overarching mission to combat the pressing issue of antimicrobial resistance, emphasizing health equity promotion and community well-being.

#USAAW #AntimicrobialResistance #HealthEquity #AcurxPharma

New To The Street Announces Episode 530 with Six Corporate Interviews, Airing on the Fox Business Network, Monday, November 20, 2023, at 10:30 PM PT
 
https://lnkd.in/et8yVcuD
 
#nasdaq #acxp #antibiotics #acurx
Acurx Pharmaceuticals Inc David Luci

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
 
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2023.  
 
https://lnkd.in/ezQaDtqj
 
#nasdaq #acxp #antibiotics #acurx
Acurx Pharmaceuticals Inc David Luci

November is C. diff Awareness Month, a time to focus on raising awareness about the severity of Clostridioides difficile (C. diff) infections. This condition affects nearly half a million people in the United States each year, resulting in approximately 29,300 deaths.
 
Join Acurx Pharmaceuticals Inc as we work diligently to protect patients and combat C. diff infections year-round. Together, we can make a difference and save lives.
 
#CdiffAwareness #HealthAwareness #nasdaq #acurx

Honoring all those who served and continue to serve in the United States Armed Forces. 

Thank you for your service.

#VeteransDay #ThankYouVeterans #Heroes #Gratitude #Acurx #acxp Acurx Pharmaceuticals Inc

https://lnkd.in/ejT7NxvC

#nasdaq #acxp #antibiotics #acurx
Acurx Pharmaceuticals Inc David Luci

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue
gross profit
selling and marketing expenses					-8.53B -
general and administrative expenses	2.42M -	2.40M 1.00%	10.78M 349.89%	7.34M 31.95%	8.53B 116,193.05%
selling general and administrative expenses	2.42M -	2.40M 1.00%	10.78M 349.89%	7.34M 31.95%	8.53M 16.29%
research and development expenses	3.51M -	2.20M 37.24%	2.03M 7.84%	4.75M 134.18%	6.04M 27.12%
other expenses
cost and expenses	5.93M -	4.60M 22.44%	12.81M 178.57%	12.09M 5.63%	14.58M 20.55%
operating expenses	5.93M -	4.60M 22.44%	12.81M 178.57%	12.09M 5.63%	14.58M 20.55%
interest expense				-1.22K -
ebitda	-5.93M -	-4.60M 22.44%	-12.88M 180.01%	-12.09M 6.12%	-14.58M 20.55%
operating income	-5.93M -	-4.60M 22.44%	-12.88M 180.01%	-12.09M 6.11%	-14.58M 20.54%
depreciation and amortization	5.93K -	4.60K 22.44%	12.81K 178.56%	1.22K 90.45%
total other income expenses net	-3 -	2 166.67%	133.01K 6,650,200%	1.22K 99.08%	2 99.84%
income before tax	-5.93M -	-4.60M 22.44%	-12.75M 177.12%	-12.09M 5.14%	-14.58M 20.55%
income tax expense	-5.93K -	-4.60K 22.52%	-66.50K 1,346.33%	-1.22K 98.16%
net income	-5.93M -	-4.60M 22.44%	-12.68M 175.68%	-12.09M 4.65%	-14.58M 20.56%
weighted average shs out	9.92M -	9.92M 0%	10.22M 3.02%	10.82M 5.88%	12.67M 17.15%
weighted average shs out dil	9.92M -	9.92M 0%	10.22M 3.02%	10.82M 5.88%	12.67M 17.15%
eps	-0.60 -	-0.46 23.33%	-1.24 169.57%	-1.12 9.68%	-1.15 2.68%
epsdiluted	-0.60 -	-0.46 23.33%	-1.24 169.57%	-1.12 9.68%	-1.15 2.68%

COM:ACURXPHARMA

Acurx Pharmaceuticals, Inc.

Last Close

2.21

30/08 20:00

Market Cap

34.97M

Beta: -

Volume Today

31.32K

Avg: -

Preview